Anew Labs
An AI drug-discovery company that combines molecular models, experimental biology and a drug pipeline to identify and develop new medicines.
$290MFunding
Lead5C
5Y Capital
Activity from announced rounds
Activity in this selectionAI
5Y Capital is the Chinese investment firm named in Dify’s announcement and connected to Anew through retained records.
Recorded funding activity
Dify supports AI application development. Anew combines models and experiments for medicines, while Syneron and Excalipoint develop different therapeutic technologies. These company events remain separate under the same firm-level identity.
- Rounds participated in
- 3
- Confirmed lead rounds
- 1 2 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $470M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionSyneron Bio
Develops intelligent platform-driven macrocyclic peptide drug discovery
$150MSeries B
Role not disclosedDify
Helps teams build deploy and operate production-grade AI applications and agentic workflows
$30MPre-Series A
Role not disclosed